Development of 1,2,3‐Triazoles as Dual Enzyme Inhibitors Targeting α‐Amylase and α‐Glucosidase for Type 2 Diabetes Intervention

View Full Paper

Ask AI

Bookmark

Authors

Discussion

This study demonstrates dual inhibition of α‐amylase and α‐glucosidase in type 2 diabetes, suggesting potential for new therapeutic agents.

Compound 6a showed potent α‐glucosidase inhibition (IC50 = 22.15 µM), comparable to acarbose (IC50 = 21.07 µM).
Compound 6h exhibited strong α‐amylase inhibition (IC50 = 84.46 µM), better than acarbose (IC50 = 87.62 µM).
Most active compounds showed moderate cytotoxicity (IC50 values ~32.87 µM), indicating a reasonable safety margin.
DPPH assay results revealed good antioxidant activity among compounds (IC50 ranging from 39.60 to 99.45 µM).

Sruthi et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

This study demonstrates dual inhibition of α‐amylase and α‐glucosidase in type 2 diabetes, suggesting potential for new therapeutic agents.